Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Andexxa (andexanet alfa), the only specific anti-Xa reversal agent, has been withdrawn from the US market on December 22, 2025.
It was marketed for the reversal of Rivaroxaban and Apixaban.
The theory was great, but it was very expensive and had a higher thrombotic risk than when PCC was used for reversal.
Below is the announcement on the FDA website.
As far as I know, it is still being sold and used in Europe, but I can not see this continuing.
There is nothing on the EMA website.
Also, rather surprisingly, there is no mention of this on the AstraZeneca US or UK websites about this.
Do their medical communication teams not work in the second part of December?”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 3, 2026, 17:59A Free Hemoglobin Screening Camp for Kaikadi Vasti and Eramushti Community Women – Hope Foundation Sironcha
-
Apr 3, 2026, 17:53Carlos Henrique Del Carlo: HFpEF and Iron Deficiency – Why Treating the Mitochondrial Engine Matters More Than We Thought?
-
Apr 3, 2026, 17:46Michelle Leona Cecil: A Call to Protect Patient Care and The Nation’s Blood Supply for Blood Disorders Community
-
Apr 3, 2026, 17:38Shahab Sheikhalishahi: A Rare Case of Portal Vein Thrombosis After Echis Carinatus Envenomation
-
Apr 3, 2026, 17:33Kimberly Ha: Epia Neuro Aims to Restore Movement in Stroke Survivors
-
Apr 3, 2026, 17:28Ryan Perry: Heart and Stroke Announces 2026 Grants-in-Aid Indigenous Research Stream Funding Opportunity
-
Apr 3, 2026, 17:21Maxime Dely: A Meaningful Journey of 14 years in Blood Transfusion
-
Apr 3, 2026, 17:19Arun V J: Don’t Miss TRANSCON 2026 – A Direct Pathway Into India’s Clinical and Institutional Network
-
Apr 3, 2026, 17:17Louise St. Germain Bannon: Preparating for ISTH 2026 and Highlighting Best Aspects of Congress